JB Capital LLC Increases Stock Position in Amgen Inc. (NASDAQ:AMGN)

JB Capital LLC grew its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.6% in the 4th quarter, HoldingsChannel reports. The firm owned 12,068 shares of the medical research company’s stock after acquiring an additional 528 shares during the quarter. JB Capital LLC’s holdings in Amgen were worth $3,146,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently modified their holdings of the company. Capital Performance Advisors LLP purchased a new stake in Amgen in the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen during the third quarter valued at about $29,000. Matrix Trust Co purchased a new position in shares of Amgen during the third quarter valued at approximately $36,000. Heck Capital Advisors LLC purchased a new stake in shares of Amgen in the 4th quarter worth about $36,000. Finally, Livelsberger Financial Advisory bought a new position in shares of Amgen in the 3rd quarter worth approximately $56,000. Institutional investors own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

AMGN has been the subject of a number of recent research reports. William Blair reiterated an “outperform” rating on shares of Amgen in a research note on Tuesday, November 12th. Deutsche Bank Aktiengesellschaft lowered their price target on Amgen from $305.00 to $285.00 in a report on Wednesday, November 27th. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price target on shares of Amgen in a research report on Tuesday, October 22nd. Finally, Wells Fargo & Company decreased their price objective on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating on the stock in a research report on Friday, January 10th. Two investment analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $314.00.

Amgen Stock Up 0.5 %

Shares of NASDAQ AMGN opened at $285.42 on Monday. Amgen Inc. has a 1 year low of $253.30 and a 1 year high of $346.85. The company has a market capitalization of $153.42 billion, a price-to-earnings ratio of 36.55, a price-to-earnings-growth ratio of 2.85 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a current ratio of 1.32 and a quick ratio of 0.96. The business has a 50-day moving average of $271.06 and a two-hundred day moving average of $304.33.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be paid a $2.38 dividend. This is a positive change from Amgen’s previous quarterly dividend of $2.25. This represents a $9.52 annualized dividend and a yield of 3.34%. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio is currently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.